LEADER 02321oam  2200649   450 
001 9910711819703321
005 20220407084718.0
035   $a(CKB)5470000002487888
035   $a(OCoLC)1085546440
035   $a(EXLCZ)995470000002487888
100   $a20190213d2019      ua             0
101 0 $aeng
135   $aurbn||||a||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aExamining how covered entities utilize the 340B drug pricing program $ehearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Fifteenth Congress, first session, October 11, 2017
210  1$aWashington :$cU.S. Government Publishing Office,$d2019.
215   $a1 online resource (iii, 184 pages) $cphotographs
300   $a"Serial No. 115-63."
320   $aIncludes bibliographical references.
517   $aExamining how covered entities utilize the 340B drug pricing program 
606   $aPrescription pricing$xGovernment policy$zUnited States
606   $aPoor$xPharmaceutical assistance$zUnited States
606   $aOlder people$xPharmaceutical assistance$zUnited States
606   $aOlder people$xPharmaceutical assistance$2fast
606   $aPoor$xPharmaceutical assistance$2fast
606   $aPrescription pricing$xGovernment policy$2fast
607   $aUnited States$2fast
608   $aLegislative hearings.$2fast
608   $aLegislative hearings.$2lcgft
615  0$aPrescription pricing$xGovernment policy
615  0$aPoor$xPharmaceutical assistance
615  0$aOlder people$xPharmaceutical assistance
615  7$aOlder people$xPharmaceutical assistance.
615  7$aPoor$xPharmaceutical assistance.
615  7$aPrescription pricing$xGovernment policy.
801  0$bGPO
801  1$bGPO
801  2$bGPO
801  2$bMERUC
801  2$bTEU
801  2$bOCLCO
801  2$bNKF
801  2$bOCLCF
801  2$bOCLCO
801  2$bTXR
801  2$bOCLCO
801  2$bCOO
801  2$bOSO
801  2$bOCLCO
801  2$bOCLCQ
801  2$bGPO
906   $aBOOK
912   $a9910711819703321
996   $aExamining how covered entities utilize the 340B drug pricing program$93449926
997   $aUNINA